Drug Trial Radar · NCT03594110
EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)
Last checked: Nov 19, 2026Latest source record: Jul 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6,609
Actual
Start
Jan 31, 2019
Primary completion
Jul 5, 2022
Study completion Jul 2, 2024
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- Collaborators
- University of Oxford; Eli Lilly and Company
- First posted
- Jul 20, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary aim of the study is to investigate the effect of empagliflozin on kidney disease progression or cardiovascular death versus placebo on top of standard of care in patients with pre-existing chronic kidney disease. After completion of the interventional part of the study (primary study completion) a subset of participants will be followed up in a post-trial observational (non-interventional) manner for cardio-renal outcomes (estimated study completion date).
Conditions
- Chronic Kidney Disease
Interventions
EmpagliflozinDrug
Taken daily with or without food
Matching placeboDrug
Taken daily with or without food
Primary outcomes
What the sponsor says the trial is designed to measure.
- Interventional Part: Time to First Occurrence of Kidney Disease Progression or Cardiovascular Death ('as Adjudicated')Time frame: From the day of randomisation to the day of the final follow-up visit in the interventional part of the trial, up to 1136 days.
- Overall Study: Time to the First Occurrence of Kidney Disease Progression or Cardiovascular Death ('as Adjudicated')Time frame: From the day of randomization in the interventional part of the trial until the individual day of end of study in the non-interventional part of the trial. Up to 1869 days.
Locations
240 sites in 8 countries. Site status is shown where the registry gives one.
Nephrology Consultants, LLC
Huntsville, Alabama
Aventiv Research, Inc
Mesa, Arizona
Southern California Permanente Medical Group
San Diego, California
University of California Los Angeles
Sylmar, California
University of California Los Angeles
Torrance, California
Yale University School of Medicine
New Haven, Connecticut
Chase Medical Research, LLC
Thomaston, Connecticut
Midland Florida Clinical Reearch Center, LLC
DeLand, Florida
University of Florida
Gainesville, Florida
East Coast Institute for Research, LLC
Jacksonville, Florida
East Coast Clinical Research, Inc
Lake City, Florida
Total Research Group, LLC
Miami, Florida
Hanson Clinical Research Center, Inc.
Port Charlotte, Florida
Emory University
Atlanta, Georgia
The Jones Center for Diabetes and Endocrine Wellness
Macon, Georgia
Cedar Crosse Research Center
Chicago, Illinois
Northwestern University
Chicago, Illinois
University of Kansas Medical Center
Kansas City, Kansas
Saint Elizabeth Healthcare
Covington, Kentucky
Lexington VA Health Care System - Troy Bowling Campus
Lexington, Kentucky
Medstar Health Research Institute
Baltimore, Maryland
Kidney Care and Transplant Services of New England, PC
West Springfield, Massachusetts
Saint Clair Specialty Physicians
Roseville, Michigan
Clinical Research Consultants, LLC
Kansas City, Missouri
VA Southern Nevada Healthcare System
North Las Vegas, Nevada
Seacoast Kidney and Hypertension Specialists
Portsmouth, New Hampshire
SUNY Downstate Medical Center
Brooklyn, New York
Mountain Kidney and Hypertension Associates, PA
Asheville, North Carolina
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Brookview Hills Research Associates LLC
Winston-Salem, North Carolina
Wake Forest University Health Sciences
Winston-Salem, North Carolina
University Hospitals of Cleveland
Cleveland, Ohio
Cleveland Clinic
Cleveland, Ohio
Thomas Jefferson University
Philadelphia, Pennsylvania
Carolina Diabetes & Kidney Center
Sumter, South Carolina
Regional Health Clinical Research
Rapid City, South Dakota
Research Institute of Dallas
Dallas, Texas
Renal Disease Research Institute
Dallas, Texas
Academy Of Diabetes, Thyroid And Endocrine, PA
El Paso, Texas
Pioneer Research Solutions, Inc.
Houston, Texas
Showing 40 of 240 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.